跳到正文
原文
STAT 主站· Ed Silverman·· 15 天前AI 评分25

中国临床试验审批新规影响药物研发

STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and more

AI 导读

自今年5月以来,中国实施新规定限制了研究者发起的临床试验数量,仅164项获批,超过1000项提交审查。印度提议的新规要求药品若未通过政府质量测试则立即暂停生产许可,加强了对制药行业的监管。

正文

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a precious gift.” So while you tug on the ribbon, we will celebrate the notion by brewing still more cups of stimulation. As always, you are invited you to join us. Our choice today is strawberry creme. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. …

The number of investigator-initiated trials, a Chinese regulatory pathway that allowed investigators to start clinical trials without sign-off from central regulators, have slowed considerably, STAT reports. Loosened rules had enabled Chinese companies to test drugs in humans faster and cheaper and prompted U.S. companies to either come to China or push the U.S. Food and Drug Administration to adopt a similar approach. But since May, when the Chinese government issued new restrictions, 164 have been approved under the new regulations and just over 1,000 were submitted for review.

India proposed rules requiring regulators to immediately suspend manufacturing licenses for medicines that fail specified quality standards in government testing, tightening oversight of one of the world’s biggest ​pharmaceutical industries, Reuters writes. The rules would apply if government testing finds the drug fails quality standards for impurities ‌or sterility, the amount of active ingredient, or dissolution, which assesses how the drug releases that ingredient. The license would remain suspended until the ​manufacturer conducts an effective root-cause analysis and implements corrective and preventive action, and could be restored only after regulators verify those measures have been implemented.

Continue to STAT+ to read the full story…

来源:STAT 主站 · statnews.com